Adalimumab Market By Disease (Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis & others), By Type (Adalimumab, Adalimumab Biosimilar), By End-Users (Hospitals, Specialty Clinics & Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027

Report Code: HCR 0100 Report Format: PDF + Excel

Adalimumab Market Overview

Adalimumab Market Size is estimated to reach $5.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 5.1% over the forecast period of 2022-2027. Adalimumab is a monoclonal antibody and disease-modifying antirheumatic medication that acts by inactivating tumor necrosis factor-alpha. It is marketed under the brand names Humira and Exemptia, among others. The original adalimumab drug is sold under the brand name Humira. New versions of adalimumab are known as adalimumab biosimilars. Biosimilars are similar versions of original biological medicines. Adalimumab is a drug used to treat rheumatoid arthritis and ankylosing spondylitis which affects the musculoskeletal system, Crohn’s disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and other diseases. It was first introduced in the United States by Abbvie and was approved by the FDA in 2002. It is used to alleviate inflammation by acting on the immune system. The growing prevalence of arthritis and skin disorders, adoption of a sedentary lifestyle, and growing obese population are some of the factors driving the Adalimumab Market growth during the forecast period 2022-2027.

Adalimumab Market

Report Coverage

The report: “Adalimumab Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Adalimumab Market.

By Disease- Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others.
By Type- Adalimumab, Adalimumab Biosimilar.
By End-Users- Hospitals, Specialty Clinics, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of psoriasis arthritis, highly informed people knowing the benefits of adalimumab, and high healthcare expenditure. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to increasing prevalence of Crohn's disease and ulcerative colitis., demand for better healthcare facilities as well a boost in the investments done by government and private companies in pharma industry. The proliferation of Rheumatoid arthritis is predicted to augment the market growth during the forecast period of 2022-2027.
  • The growing prevalence of arthritis and skin disorders is estimated to drive the market growth of the Adalimumab Market. High cost as well as lack side effects of adalimumab poses threat to the market growth.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Adalimumab Market Report.

Adalimumab Market: Market Share (%) by region, 2021

Adalimumab Market

For more details on this report - Request for Sample

Adalimumab Market Segmentation Analysis- By Disease

Adalimumab Market based on the disease can be further segmented into Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others. Rheumatoid arthritis held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 7.8% over the forecast period of 2022-2027. Rheumatoid arthritis is a chronic inflammatory disorder that affects several joints, especially the hands and feet. The immune system of the body targets its own tissue, such as joints and muscles and attacks the internal organs in extreme cases. According to the estimations of the World Health Organisation (WHO) in 2021, around 14 million people live with Rheumatoid arthritis. The inflammation caused by rheumatoid arthritis can cause harm to other parts of the body as well. Cigarette smoking and excessive weight increase the risk of Rheumatoid arthritis. As per the estimations of the World Obesity Federation, 2.7 billion adults will be overweight, over 1 billion affected by obesity, and 177 million adults will be severely affected by obesity by 2025, propelling the prevalence of rheumatoid arthritis.

Adalimumab Market Segmentation Analysis- By End User

Adalimumab Market based on end-user can be further segmented into Hospitals, Specialty Clinics, and others. The hospital's segment held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 6.1% over the forecast period of 2022-2027 owing to increased healthcare infrastructure’s spending by countries, technological advancements in the hospital industry and increasing prevalence of arthritis requiring hospitalizations. According to the Centers for Disease Control and Prevention, Osteoarthritis accounted for more than $16 billion of the combined cost for all hospitalizations in the U.S. in 2020. Moreover, as per the estimations of Cureus Journal of Medical science, more than 560,000 hospitalizations in the U.S. were owing to rheumatoid arthritis in 2020, propelling the growth of the hospital's segment.

Adalimumab Market Segmentation Analysis- By Geography

The Adalimumab Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the rest of the World. North America held a dominant market share of 33% in the year 2021 as compared to the other counterparts on account of increased awareness about the effectiveness of adalimumab in treating arthritis, rising prevalence of psoriasis arthritis, FDA approvals for adalimumab biosimilars, and high healthcare spending. According to the National Psoriasis Foundation, more than 8 million people in the U.S. have psoriasis.

However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR of 7.2% over the forecast period of 2022-2027 on account of rising healthcare expenditure, demand for better healthcare facilities, and increasing prevalence of inflammatory bowel disease (IBD) which includes Crohn's disease and ulcerative colitis. IBD is getting more common, complex, and severe in Australia, according to Crohn's & Colitis. It affects about 1 in 250 adults aged 5 to 40. Crohn's disease or ulcerative colitis affects nearly 75,000 Australians, with the number expected to rise to 100,000 by 2022. Furthermore, the number of Canadians suffering from IBD is predicted to reach 400,000 by 2030, propelling market growth.

Adalimumab Market Drivers

The growing prevalence of arthritis disorders is boosting the market growth.

According to the CDC, 54.4 million US individuals have some type of arthritis, a number that is projected to rise to 78 million by 2040. Disorders associated with arthritis include inflammation of one or more joints, resulting in pain, swelling, and stiffness. Adalimumab is used to decrease the pain and swelling as well as slow down the progress of arthritis. Adalimumab is primarily used for treating active enthesitis-related arthritis, Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, Osteoarthritis, and others. Growing geriatric population, sedentary lifestyle, and growing prevalence of obesity increase the risk of psoriasis and rheumatoid arthritis. The increasing prevalence of Crown’s disease is estimated to propel the market growth as Crohn's disease increases the risk for arthritis. According to the Crohn's & Colitis Foundation, approximately 30% of Crohn's disease patients develop arthritis, thereby driving the Adalimumab Industry growth.

Skin Disorder Proliferation is Driving Market Growth

According to the World Health Organisation (WHO), around 900 million people in the world suffer from skin diseases at any given point in time. Adalimumab targets a protein in the body called tumor necrosis factor-alpha (TNF-alpha), which is a key player in the inflammatory process that triggers skin disorders including psoriasis. Psoriasis is a skin disorder that causes red, itchy scaly spots on the knees, elbows, trunk, and scalp. Adalimumab suppresses the hyperactive immune system response that triggers psoriasis. As per the estimations of the National Psoriasis Foundation, 125 million people worldwide which accounts for 2 to 3 percent of the total population, have psoriasis, propelling the market growth.

Adalimumab Market Challenges

Side effects and the high cost of adalimumab pose a threat to market growth.

Adalimumab costs around USD 2000-3000 per infusion, which makes it quite expensive for people living in low and middle-income countries. Furthermore, the side effects of adalimumab are estimated to impede the market growth. Some of the common side effects of adalimumab are fever, swollen glands, night sweats, general feeling of illness, joint and muscle pain, skin rash, easy bruising or bleeding, and others. Adalimumab can also induce a lethal kind of lymphoma or cancer of the liver, spleen, and bone marrow. This primarily occurs in teenagers and young men suffering from Crohn's disease or ulcerative colitis, hampering the market growth.

Adalimumab Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Adalimumab Market. The top 10- Adalimumab Market companies are-

  1. Croda International Plc
  2. AbbVie Inc
  3. Clariant AG
  4. Novartis AG
  5. AkzoNobel N.V
  6. F. Hoffmann-La Roche Ltd.
  7. Evonik Industries
  8. PolyOne Corporation
  9. DuPont
  10. Addcomp Holland

Recent Developments

  • In June 2021, Celltrion Healthcare won approval by European Commission for marketing its subcutaneous infliximab biosimilar, Remsima for new and existing RA patients and it launched Remsima in Canada for the treatment of adult patients with RA.
  • In February 2021, Sandoz Canada, a Pharmaceutical and Medicine Manufacturing company launched an adalimumab biosimilar named Hyrimoz in Canada. On November 4, 2020, Health Canada approved Hyrimoz to treat nine of the 12 indications of the reference biological Humira. 
  • In February 2021, Japan-based Fujifilm Kyowa Kirin Biologics in partnership with US-based drugmaker Viatris announced the launch of an adalimumab biosimilar named Adalimumab Biosimilar 1 in Japan. The biosimilar was approved by Japan's regulatory body in June 2020 and it will be the country's first adalimumab biosimilar to be launched.

Relevant Titles

Report Code: HCR 16877

Report Code: HCR 70167

For more Lifesciences and Healthcare related reports, please click here

1. Adalimumab Market - Overview
    1.1  Definitions and Scope
2. Adalimumab Market - Executive Summary
3. Adalimumab Market - Comparative Analysis
    3.1 Company Benchmarking
    3.2 Global Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Adalimumab Market - Startup Companies Scenario Premium
    4.1  Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Adalimumab Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Adalimumab Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Adalimumab Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Adalimumab Market – By Disease
    8.1 Crohn’s disease
    8.2 Psoriatic arthritis
    8.3 Rheumatoid arthritis
    8.4 Ulcerative colitis
    8.5 Others
9. Adalimumab Market – By Type
    9.1 Adalimumab
    9.2 Adalimumab Biosimilar
10.  Adalimumab Market – By End User
    10.1 Hospitals
    10.2 Specialty Clinics
    10.3 Others
11. Adalimumab Market - By Geography
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Adalimumab Market - Entropy
13. Adalimumab Market – Industry/Segment Competition Landscape      Premium  
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Adalimumab Market – Key Company List by Country Premium Premium
15. Adalimumab Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
List of Tables

Table 1: Adalimumab Market Overview 2021-2026
Table 2: Adalimumab Market Leader Analysis 2018-2019 (US$)
Table 3: Adalimumab Market Product Analysis 2018-2019 (US$)
Table 4: Adalimumab Market End User Analysis 2018-2019 (US$)
Table 5: Adalimumab Market Patent Analysis 2013-2018* (US$)
Table 6: Adalimumab Market Financial Analysis 2018-2019 (US$)
Table 7: Adalimumab Market Driver Analysis 2018-2019 (US$)
Table 8: Adalimumab Market Challenges Analysis 2018-2019 (US$)
Table 9: Adalimumab Market Constraint Analysis 2018-2019 (US$)
Table 10: Adalimumab Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Adalimumab Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Adalimumab Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Adalimumab Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Adalimumab Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Adalimumab Market Value Chain Analysis 2018-2019 (US$)
Table 16: Adalimumab Market Pricing Analysis 2021-2026 (US$)
Table 17: Adalimumab Market Opportunities Analysis 2021-2026 (US$)
Table 18: Adalimumab Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Adalimumab Market Supplier Analysis 2018-2019 (US$)
Table 20: Adalimumab Market Distributor Analysis 2018-2019 (US$)
Table 21: Adalimumab Market Trend Analysis 2018-2019 (US$)
Table 22: Adalimumab Market Size 2018 (US$)
Table 23: Adalimumab Market Forecast Analysis 2021-2026 (US$)
Table 24: Adalimumab Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 26: Adalimumab Market By Application, Revenue & Volume,By Rheumatoid Arthritis, 2021-2026 ($)
Table 27: Adalimumab Market By Application, Revenue & Volume,By Psoriasis, 2021-2026 ($)
Table 28: Adalimumab Market By Application, Revenue & Volume,By Chron’s Disease, 2021-2026 ($)
Table 29: Adalimumab Market By Application, Revenue & Volume,By Ulcerative Colitis, 2021-2026 ($)
Table 30: North America Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 31: South america Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 32: Europe Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 33: APAC Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 34: Middle East & Africa Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 35: Russia Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 36: Israel Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 37: Top Companies 2018 (US$) Adalimumab Market, Revenue & Volume
Table 38: Product Launch 2018-2019 Adalimumab Market, Revenue & Volume
Table 39: Mergers & Acquistions 2018-2019 Adalimumab Market, Revenue & Volume


List of Figures
Figure 1: Overview of Adalimumab Market 2021-2026
Figure 2: Market Share Analysis for Adalimumab Market 2018 (US$)
Figure 3: Product Comparison in Adalimumab Market 2018-2019 (US$)
Figure 4: End User Profile for Adalimumab Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Adalimumab Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Adalimumab Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Adalimumab Market 2018-2019
Figure 8: Ecosystem Analysis in Adalimumab Market 2018
Figure 9: Average Selling Price in Adalimumab Market 2021-2026
Figure 10: Top Opportunites in Adalimumab Market 2018-2019
Figure 11: Market Life Cycle Analysis in Adalimumab Market
Figure 12: GlobalBy ApplicationAdalimumab Market Revenue, 2021-2026 ($)
Figure 13: Global Adalimumab Market - By Geography
Figure 14: Global Adalimumab Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Adalimumab Market CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 17: US Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 59: U.K Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 92: China Adalimumab Market Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Adalimumab Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Adalimumab Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Adalimumab Market 
Figure 130: Developments, 2018-2019*Adalimumab Market 
Figure 131: Company 1 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Adalimumab Market Net Sales Share, By Geography, 2018 (%)